

1. Hoffmann, M., et al., A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. *Cancer Res* **70**, 2328-38 (2010).
2. Tzvetkov, M.V., Meineke, I., Sehrt, D., Vormfelde, S.V., and Brockmöller, J., Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. *Pharmacogenomics* **11**, 449-57 (2010).
3. Kirchheiner, J., et al., Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. *Eur J Clin Pharmacol* **65**, 19-31 (2009).
4. Kuhne, A., Tzvetkov, M.V., Hagos, Y., Lage, H., Burckhardt, G., and Brockmöller, J., Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. *Biochem Pharmacol* **78**, 45-53 (2009).
5. Lotsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmöller, J., and Geisslinger, G., Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? *Pain* **144**, 119-24 (2009).
6. Sachse-Seeboth, C., et al., Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. *Clin Pharmacol Ther* **85**, 273-6 (2009).
7. Schirmer, M.A., et al., Bioinformatic and functional analysis of TGFBR1 polymorphisms. *Pharmacogenet Genomics* **19**, 249-59 (2009).
8. Tzvetkov, M.V., et al., The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. *Clin Pharmacol Ther* **86**, 299-306 (2009).
9. Vormfelde, S.V., et al., Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. *Clin Pharmacol Ther* **86**, 54-61 (2009).
10. Vormfelde, S.V., Toliat, M.R., Nurnberg, P., and Brockmöller, J., Atrial natriuretic peptide polymorphisms, hydrochlorothiazide and urinary potassium excretion. *Int J Cardiol* (2009).
11. Brockmöller, J. and Tzvetkov, M.V., Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. *Eur J Clin Pharmacol* **64**, 133-57 (2008).
12. He, Y.J., Brockmöller, J., Schmidt, H., Roots, I., and Kirchheiner, J., CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? *J Anal Toxicol* **32**, 178-82 (2008).
13. Kassner, N., et al., Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. *Drug Metab Dispos* **36**, 2113-20 (2008).
14. Kirchheiner, J., Keulen, J.T., Bauer, S., Roots, I., and Brockmöller, J., Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. *J Clin Psychopharmacol* **28**, 78-83 (2008).
15. Kirchheiner, J., et al., Genetic variants in FKBP5 affecting response to antidepressant drug treatment. *Pharmacogenomics* **9**, 841-6 (2008).
16. Kirchheiner, J., Meineke, I., Fuhr, U., Rodriguez-Antona, C., Lebedeva, E., and Brockmöller, J., Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyecosatrienoic acids. *Pharmacogenomics* **9**, 277-88 (2008).
17. Kube, D., et al., Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. *Clin Cancer Res* **14**, 3777-84 (2008).
18. Kuhne, A., et al., Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. *Clin Pharmacol Ther* **83**, 749-57 (2008).

19. Meineke, C., et al., Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. *Pharmacogenet Genomics* **18**, 219-30 (2008).
20. Schirmer, M., Hoffmann, M., Kaya, E., Tzvetkov, M., and Brockmöller, J., Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. *Pharmacogenomics J* **8**, 297-304 (2008).
21. Seeringer, A., Brockmöller, J., Bauer, S., and Kirchheiner, J., Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. *Eur J Clin Pharmacol* **64**, 883-8 (2008).
22. Tzvetkov, M.V., Brockmöller, J., Roots, I., and Kirchheiner, J., Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. *Pharmacogenet Genomics* **18**, 495-506 (2008).
23. Vormfelde, S.V., Toliat, M.R., Schirmer, M., Meineke, I., Nurnberg, P., and Brockmöller, J., The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther* **83**, 815-7 (2008).
24. Brockmöller, J., Meineke, I., and Kirchheiner, J., Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. *Clin Pharmacol Ther* **81**, 699-707 (2007).
25. Hagos, Y., Bahn, A., Vormfelde, S.V., Brockmöller, J., and Burckhardt, G., Torasemide transport by organic anion transporters contributes to hyperuricemia. *J Am Soc Nephrol* **18**, 3101-9 (2007).
26. Kirchheiner, J., Nickchen, K., Sasse, J., Bauer, M., Roots, I., and Brockmöller, J., A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. *Pharmacogenomics J* **7**, 48-55 (2007).
27. Kirchheiner, J., et al., Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. *Pharmacogenomics J* **7**, 257-65 (2007).
28. Kube, D., et al., The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. *Genes Immun* **8**, 164-7 (2007).
29. Kuhne, A., et al., Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. *Pharmacogenet Genomics* **17**, 505-17 (2007).
30. Meineke, I. and Brockmöller, J., Simulation of complex pharmacokinetic models in Microsoft Excel. *Comput Methods Programs Biomed* **88**, 239-45 (2007).
31. Mossner, R., et al., Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. *Arch Dermatol Res* **298**, 371-9 (2007).
32. Mossner, R., et al., Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. *Cancer Lett* **246**, 218-23 (2007).
33. Roots, I., et al., Genotype and phenotype relationship in drug metabolism. *Ernst Schering Res Found Workshop*, 81-100 (2007).
34. Tzvetkov, M.V., Meineke, C., Oetjen, E., Hirsch-Ernst, K., and Brockmöller, J., Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. *Gene* **386**, 52-62 (2007).
35. Vormfelde, S.V. and Brockmöller, J., On the value of haplotype-based genotype-phenotype analysis and on data transformation in pharmacogenetics and -genomics. *Nat Rev Genet* **8** (2007).
36. Vormfelde, S.V., et al., Genetic variation at the CYP2C locus and its association with torsemide biotransformation. *Pharmacogenomics J* **7**, 200-11 (2007).
37. Vormfelde, S.V., et al., Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. *Clin Pharmacol Ther* **82**, 300-9 (2007).

38. Brockmöller, J., Junker, K., and Multhoff, G., [New perspectives in the management of non-small-cell lung carcinoma (NSCLC)]. *Onkologie* **29 Suppl 2**, 25-8 (2006).
39. Engelhardt, S., Meineke, I., and Brockmöller, J., Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. *J Chromatogr B Analyt Technol Biomed Life Sci* **831**, 31-5 (2006).
40. Heller, T., et al., AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. *Ther Drug Monit* **28**, 673-7 (2006).
41. Kamdem, L.K., Meineke, I., Godtel-Armbrust, U., Brockmöller, J., and Wojnowski, L., Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. *Chem Res Toxicol* **19**, 577-86 (2006).
42. Kersting, G., et al., Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. *Naunyn Schmiedebergs Arch Pharmacol* **374**, 21-30 (2006).
43. Kirchheiner, J., Seeringer, A., and Brockmöller, J., [State of the art of pharmacogenetic diagnostics in drug therapy]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* **49**, 995-1003 (2006).
44. Kirchheiner, J., et al., Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. *Clin Pharmacol Ther* **80**, 657-67 (2006).
45. Lotsch, J., et al., Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. *Clin Pharmacol Ther* **79**, 72-89 (2006).
46. Meineke, I., Steinmetz, H., Kirchheiner, J., and Brockmöller, J., Therapeutic drug monitoring of mirtazapine, desmethyilmirtazapine, 8-hydroxymirtazapine, and mirtazapine-N-oxide by enantioselective HPLC with fluorescence detection. *Ther Drug Monit* **28**, 760-5 (2006).
47. Rogausch, A., Prause, D., Schallenberg, A., Brockmöller, J., and Himmel, W., Patients' and physicians' perspectives on pharmacogenetic testing. *Pharmacogenomics* **7**, 49-59 (2006).
48. Schirmer, M., et al., Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. *Pharmacogenet Genomics* **16**, 59-71 (2006).
49. Vormfelde, S.V., et al., Anxiety- and novelty seeking-related personality traits and serotonin transporter gene polymorphisms. *J Psychiatr Res* **40**, 568-76 (2006).
50. Vormfelde, S.V., et al., Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. *Br J Clin Pharmacol* **62**, 323-35 (2006).
51. Vormfelde, S.V., Sehrt, D., Bolte, D., Pahl, S., Tzvetkov, M., and Brockmöller, J., Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. *Eur J Clin Pharmacol* **62**, 195-201 (2006).
52. Brockmöller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H., and Roots, I., Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. *Clin Pharmacol Ther* **77**, 529-41 (2005).
53. Holstein, A., et al., Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. *Br J Clin Pharmacol* **60**, 103-6 (2005).
54. Kamdem, L.K., et al., Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. *Clin Chem* **51**, 1374-81 (2005).
55. Kirchheiner, J. and Brockmöller, J., Clinical consequences of cytochrome P450 2C9 polymorphisms. *Clin Pharmacol Ther* **77**, 1-16 (2005).
56. Kirchheiner, J., Fuhr, U., and Brockmöller, J., Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? *Nat Rev Drug Discov* **4**, 639-47 (2005).
57. Kirchheiner, J., et al., Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. *Pharmacogenet Genomics* **15**, 579-87 (2005).

58. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., and Brockmüller, J., Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. *Clin Pharmacokinet* **44**, 1209-25 (2005).
59. Kirchheiner, J., Sasse, J., Roots, I., Brockmüller, J., and Bauer, M., [The value of pharmacogenetic tests in antidepressive medication therapy]. *Nervenarzt* **76**, 1340-54 (2005).
60. Kulle, B., et al., Application of genomewide SNP arrays for detection of simulated susceptibility loci. *Hum Mutat* **25**, 557-65 (2005).
61. Raimondi, S., et al., Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. *Mutat Res* **592**, 45-57 (2005).
62. Rogausch, A., Brockmüller, J., and Himmel, W., [Pharmacogenetics in future medical care -- implications for patients and physicians]. *Gesundheitswesen* **67**, 257-63 (2005).
63. Tzvetkov, M.V., Becker, C., Kulle, B., Nurnberg, P., Brockmüller, J., and Wojnowski, L., Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification. *Electrophoresis* **26**, 710-5 (2005).
64. Wojnowski, L., et al., NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation* **112**, 3754-62 (2005).
65. Burk, O., et al., The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). *J Biol Chem* **279**, 38379-85 (2004).
66. Jetter, A., et al., Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. *Eur J Clin Pharmacol* **60**, 165-71 (2004).
67. Johne, A., et al., Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. *Eur J Clin Pharmacol* **60**, 617-22 (2004).
68. Jonsson, E.G., Kaiser, R., Brockmüller, J., Nimgaonkar, V.L., and Crocq, M.A., Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. *Psychiatr Genet* **14**, 9-12 (2004).
69. Kaiser, R., Tremblay, P.B., Sezer, O., Possinger, K., Roots, I., and Brockmüller, J., Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. *Pharmacogenetics* **14**, 271-8 (2004).
70. Kamdem, L.K., Meineke, I., Koch, I., Zanger, U.M., Brockmüller, J., and Wojnowski, L., Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. *Naunyn Schmiedebergs Arch Pharmacol* **370**, 71-7 (2004).
71. Kirchheiner, J., et al., Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther* **76**, 302-12 (2004).
72. Kirchheiner, J., Henckel, H.B., Meineke, I., Roots, I., and Brockmüller, J., Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. *J Clin Psychopharmacol* **24**, 647-52 (2004).
73. Kirchheiner, J., et al., Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. *Clin Pharmacokinet* **43**, 267-78 (2004).
74. Kirchheiner, J., et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry* **9**, 442-73 (2004).
75. Kirchheiner, J., et al., Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. *Pharmacogenetics* **14**, 19-26 (2004).
76. Meineke, I., Kress, I., Poser, W., Ruther, E., and Brockmüller, J., Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection. *Ther Drug Monit* **26**, 277-83 (2004).
77. Mossner, R., et al., Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. *Arch Dermatol Res* **296**, 1-5 (2004).

78. Roots, I., et al., Pharmacogenetics-based new therapeutic concepts. *Drug Metab Rev* **36**, 617-38 (2004).
79. Smits, K.M., et al., Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. *Int J Cancer* **110**, 266-70 (2004).
80. Ufer, M., et al., Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. *Xenobiotica* **34**, 847-59 (2004).
81. Vormfelde, S.V., et al., CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. *Clin Pharmacol Ther* **76**, 557-66 (2004).
82. Wojnowski, L. and Brockmöller, J., Single nucleotide polymorphism characterization by mRNA expression imbalance assessment. *Pharmacogenetics* **14**, 267-9 (2004).
83. Wojnowski, L., et al., Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. *Pharmacogenetics* **14**, 691-700 (2004).
84. Bachus, R., Neubert, K., Roots, I., Prudlo, J., Brockmöller, J., and Ludolph, A.C., Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* **74**, 1161 (2003).
85. Bauer, S., Störmer, E., Kirchheiner, J., Michael, C., Brockmöller, J., and Roots, I., Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. *J Pharm Biomed Anal* **31**, 551-5 (2003).
86. Gaikovitch, E.A., et al., Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. *Eur J Clin Pharmacol* **59**, 303-12 (2003).
87. Gashaw, I., et al., Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. *Clin Pharmacol Ther* **74**, 448-57 (2003).
88. Gungor, K., et al., Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. *Eur J Clin Pharmacol* **59**, 527-31 (2003).
89. Hung, R.J., et al., CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. *Carcinogenesis* **24**, 875-82 (2003).
90. Johne, A., Roots, I., and Brockmöller, J., A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. *Cancer Epidemiol Biomarkers Prev* **12**, 68-70 (2003).
91. Kaiser, R., et al., L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. *Neurology* **60**, 1750-5 (2003).
92. Kirchheiner, J., et al., Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. *Pharmacogenetics* **13**, 619-26 (2003).
93. Kirchheiner, J., et al., Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. *Clin Pharmacol Ther* **74**, 186-94 (2003).
94. Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I., and Brockmöller, J., Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *Br J Clin Pharmacol* **55**, 51-61 (2003).
95. Kirchheiner, J., Muller, G., Meineke, I., Wernecke, K.D., Roots, I., and Brockmöller, J., Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. *J Clin Psychopharmacol* **23**, 459-66 (2003).
96. Kirchheiner, J., Sasse, J., Meineke, I., Roots, I., and Brockmöller, J., Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. *Pharmacogenetics* **13**, 721-8 (2003).

97. Kirchheiner, J., Störmer, E., Meisel, C., Steinbach, N., Roots, I., and Brockmöller, J., Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. *Pharmacogenetics* **13**, 473-80 (2003).
98. Meisel, C., et al., Implications of pharmacogenetics for individualizing drug treatment and for study design. *J Mol Med* **81**, 154-67 (2003).
99. Störmer, E., Bauer, S., Kirchheiner, J., Brockmöller, J., and Roots, I., Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection. *J Chromatogr B Analyt Technol Biomed Life Sci* **783**, 207-12 (2003).
100. Taioli, E., et al., Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. *Int J Epidemiol* **32**, 60-3 (2003).
101. Tremblay, P.B., et al., Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. *J Clin Oncol* **21**, 2147-55 (2003).
102. Vormfelde, S.V., Burckhardt, G., Zirk, A., Wojnowski, L., and Brockmöller, J., Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. *Pharmacogenomics* **4**, 701-34 (2003).
103. Abraham, K., Geusau, A., Tosun, Y., Helge, H., Bauer, S., and Brockmöller, J., Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. *Clin Pharmacol Ther* **72**, 163-74 (2002).
104. Bauer, S., Störmer, E., Kaiser, R., Tremblay, P.B., Brockmöller, J., and Roots, I., Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. *Biomed Chromatogr* **16**, 187-90 (2002).
105. Bauer, S., Störmer, E., Kerb, R., Johne, A., Brockmöller, J., and Roots, I., Differential effects of Saint John's Wort (*hypericum perforatum*) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers. *Eur J Clin Pharmacol* **58**, 581-5 (2002).
106. Benhamou, S., et al., Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. *Carcinogenesis* **23**, 1343-50 (2002).
107. Brockmöller, J., et al., The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. *Clin Pharmacol Ther* **72**, 438-52 (2002).
108. Cascorbi, I., Brockmöller, J., and Roots, I., Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. *Int J Clin Pharmacol Ther* **40**, 562-3 (2002).
109. Engel, L.S., et al., Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. *Am J Epidemiol* **156**, 95-109 (2002).
110. Herken, H., et al., Frequency of the 17-bp variable number of tandem repeat polymorphism in Turkish schizophrenic patients. *Schizophr Res* **58**, 99-100 (2002).
111. Johne, A., et al., Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. *Clin Pharmacol Ther* **72**, 584-94 (2002).
112. Johne, A., et al., Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (*Hypericum perforatum*). *J Clin Psychopharmacol* **22**, 46-54 (2002).
113. Kaiser, R., et al., Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. *Am J Med Genet* **114**, 323-8 (2002).
114. Kaiser, R., et al., Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. *J Clin Oncol* **20**, 2805-11 (2002).
115. Kaiser, R., Tremblay, P.B., Klufmoller, F., Roots, I., and Brockmöller, J., Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. *Mol Psychiatry* **7**, 695-705 (2002).

116. Kaiser, R., Tremblay, P.B., Roots, I., and Brockmöller, J., Validity of PCR with emphasis on variable number of tandem repeat analysis. *Clin Biochem* **35**, 49-56 (2002).
117. Kerb, R., Brockmöller, J., Schlagenhauer, R., Sprenger, R., Roots, I., and Brinkmann, U., Influence of GSTT1 and GSTM1 genotypes on sunburn sensitivity. *Am J Pharmacogenomics* **2**, 147-54 (2002).
118. Kirchheiner, J., et al., Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. *Pharmacogenetics* **12**, 101-9 (2002).
119. Kirchheiner, J., et al., Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. *Clin Pharmacol Ther* **71**, 286-96 (2002).
120. Kirchheiner, J., Meineke, I., Freytag, G., Meisel, C., Roots, I., and Brockmöller, J., Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clin Pharmacol Ther* **72**, 62-75 (2002).
121. Kirchheiner, J., Meineke, I., Muller, G., Roots, I., and Brockmöller, J., Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. *Pharmacogenetics* **12**, 571-80 (2002).
122. Koch, I., et al., Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. *Drug Metab Dispos* **30**, 1108-14 (2002).
123. Meineke, I., et al., Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. *Br J Clin Pharmacol* **54**, 592-603 (2002).
124. Neu, P., Seyfert, S., Brockmöller, J., Dettling, M., and Marx, P., Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency. *Pharmacopsychiatry* **35**, 26-8 (2002).
125. Nowakowski-Gashaw, I., Mrozikiewicz, P.M., Roots, I., and Brockmöller, J., Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCR. *Clin Chem* **48**, 366-70 (2002).
126. Wojnowski, L., et al., Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. *J Natl Cancer Inst* **94**, 630-1; author reply 631-2 (2002).
127. Cascorbi, I., Roots, I., and Brockmöller, J., Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. *Cancer Res* **61**, 5051-6 (2001).
128. Eiselt, R., et al., Identification and functional characterization of eight CYP3A4 protein variants. *Pharmacogenetics* **11**, 447-58 (2001).
129. Garte, S., et al., Metabolic gene polymorphism frequencies in control populations. *Cancer Epidemiol Biomarkers Prev* **10**, 1239-48 (2001).
130. Hustert, E., et al., The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics* **11**, 773-9 (2001).
131. Kaiser, R., et al., Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. *Mol Psychiatry* **6**, 179-85 (2001).
132. Kerb, R., et al., The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. *Pharmacogenomics J* **1**, 204-10 (2001).
133. Kirchheiner, J., et al., CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. *Acta Psychiatr Scand* **104**, 173-92 (2001).
134. Vineis, P., et al., Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. *Cancer Epidemiol Biomarkers Prev* **10**, 1249-52 (2001).

135. Brockmöller, J., Cascorbi, I., Henning, S., Meisel, C., and Roots, I., Molecular genetics of cancer susceptibility. *Pharmacology* **61**, 212-27 (2000).
136. Brockmöller, J., Kirchheiner, J., Meisel, C., and Roots, I., Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. *Pharmacogenomics* **1**, 125-51 (2000).
137. Cascorbi, I., et al., Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. *Cancer Res* **60**, 644-9 (2000).
138. Dettling, M., et al., Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. *Psychopharmacology (Berl)* **152**, 80-6 (2000).
139. Dettling, M., et al., Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. *Pharmacopsychiatry* **33**, 218-20 (2000).
140. Hoffmeyer, S., et al., Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci U S A* **97**, 3473-8 (2000).
141. Kaiser, R., et al., Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. *Mol Psychiatry* **5**, 418-24 (2000).
142. Mai, I., et al., Hazardous pharmacokinetic interaction of Saint John's wort (*Hypericum perforatum*) with the immunosuppressant cyclosporin. *Int J Clin Pharmacol Ther* **38**, 500-2 (2000).
143. Marcus, P.M., et al., Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. *Cancer Epidemiol Biomarkers Prev* **9**, 461-7 (2000).
144. McElroy, S., et al., CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. *AAPS PharmSci* **2**, E33 (2000).
145. Meisel, C., Roots, I., Cascorbi, I., Brinkmann, U., and Brockmöller, J., How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. *Clin Chem Lab Med* **38**, 869-76 (2000).
146. Sprenger, R., et al., Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. *Pharmacogenetics* **10**, 557-65 (2000).
147. Störmer, E., Brockmöller, J., Roots, I., and Schmider, J., Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. *Psychopharmacology (Berl)* **151**, 312-20 (2000).
148. Störmer, E., Roots, I., and Brockmöller, J., Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. *Br J Clin Pharmacol* **50**, 553-61 (2000).
149. Aynacioglu, A.S., et al., Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. *Br J Clin Pharmacol* **48**, 409-15 (1999).
150. Aynacioglu, A.S., et al., Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. *Br J Clin Pharmacol* **48**, 761-4 (1999).
151. Aynacioglu, A.S., et al., Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. *Clin Pharmacol Ther* **66**, 185-92 (1999).
152. Brockmöller, J., Pharmacogenomics--science fiction come true. *Int J Clin Pharmacol Ther* **37**, 317-8 (1999).

153. Bruhn, C., Brockmöller, J., Cascorbi, I., Roots, I., and Borchert, H.H., Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). *Biochem Pharmacol* **58**, 1759-64 (1999).
154. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P.M., Muller, A., and Roots, I., Arylamine N-acetyltransferase activity in man. *Drug Metab Rev* **31**, 489-502 (1999).
155. Johne, A., Brockmöller, J., Bauer, S., Maurer, A., Langheinrich, M., and Roots, I., Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* **66**, 338-45 (1999).
156. Kerb, R., Brockmöller, J., Sachse, C., and Roots, I., Detection of the GSTM1*0 allele by long polymerase chain reaction. *Pharmacogenetics* **9**, 89-94 (1999).
157. Kleeberg, U., et al., Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation. *Drug Metab Rev* **31**, 381-92 (1999).
158. Rost, K.L., et al., Omeprazole weakly inhibits CYP1A2 activity in man. *Int J Clin Pharmacol Ther* **37**, 567-74 (1999).
159. Sachse, C., Brockmöller, J., Bauer, S., and Roots, I., Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. *Br J Clin Pharmacol* **47**, 445-9 (1999).
160. Sachse, C., et al., Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. *Clin Pharmacol Ther* **66**, 431-8 (1999).
161. Schmider, J., Brockmöller, J., Arold, G., Bauer, S., and Roots, I., Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. *Pharmacogenetics* **9**, 725-34 (1999).
162. Brockmöller, J., Cascorbi, I., Kerb, R., Sachse, C., and Roots, I., Polymorphisms in xenobiotic conjugation and disease predisposition. *Toxicol Lett* **102-103**, 173-83 (1998).
163. Bruhn, C., Brockmöller, J., Kerb, R., Roots, I., and Borchert, H.H., Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). *Biochem Pharmacol* **56**, 1189-93 (1998).
164. Frotschl, R., Chichmanov, L., Kleeberg, U., Hildebrandt, A.G., Roots, I., and Brockmöller, J., Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. *Chem Res Toxicol* **11**, 1447-52 (1998).
165. Rojas, M., et al., High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. *Pharmacogenetics* **8**, 109-18 (1998).
166. Sachse, C., Brockmöller, J., Hildebrand, M., Muller, K., and Roots, I., Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. *Pharmacogenetics* **8**, 181-5 (1998).
167. Walter, S., Bauer, S., Roots, I., and Brockmöller, J., Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B Biomed Sci Appl* **720**, 231-7 (1998).
168. Brockmöller, J., Reum, T., Bauer, S., Kerb, R., Hubner, W.D., and Roots, I., Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. *Pharmacopsychiatry* **30 Suppl 2**, 94-101 (1997).
169. Kerb, R., Brockmöller, J., Reum, T., and Roots, I., Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. *J Invest Dermatol* **108**, 229-32 (1997).
170. Mrozikiewicz, P.M., Cascorbi, I., Brockmöller, J., and Roots, I., CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. *Pharmacogenetics* **7**, 303-7 (1997).

171. Sachse, C., Brockmöller, J., Bauer, S., and Roots, I., Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. *Am J Hum Genet* **60**, 284-95 (1997).
172. Brockmöller, J., Cascorbi, I., Kerb, R., and Roots, I., Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. *Cancer Res* **56**, 3915-25 (1996).
173. Brockmöller, J., Kaiser, R., Kerb, R., Cascorbi, I., Jaeger, V., and Roots, I., Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. *Pharmacogenetics* **6**, 535-45 (1996).
174. Cascorbi, I., Brockmöller, J., Bauer, S., Reum, T., and Roots, I., NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. *Pharmacogenetics* **6**, 257-9 (1996).
175. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P.M., Bauer, S., Loddenkemper, R., and Roots, I., Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. *Cancer Res* **56**, 3961-6 (1996).
176. Cascorbi, I., Brockmöller, J., and Roots, I., A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. *Cancer Res* **56**, 4965-9 (1996).
177. Daly, A.K., et al., Nomenclature for human CYP2D6 alleles. *Pharmacogenetics* **6**, 193-201 (1996).
178. Frotschl, R., Kleeberg, U., Hildebrandt, A.G., Roots, I., and Brockmöller, J., Polymerase chain reaction (PCR)-based construction of a competitor target for quantitative reverse transcriptase PCR measurement of cytochrome P450 1A1 mRNA. *Anal Biochem* **242**, 280-2 (1996).
179. Kerb, R., Brockmöller, J., Staffeldt, B., Ploch, M., and Roots, I., Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. *Antimicrob Agents Chemother* **40**, 2087-93 (1996).
180. Mrozikiewicz, P.M., Cascorbi, I., Brockmöller, J., and Roots, I., Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. *Clin Pharmacol Ther* **59**, 376-82 (1996).
181. Patt, S., et al., p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. *Hum Pathol* **27**, 586-9 (1996).
182. Sachse, C., Brockmöller, J., Bauer, S., Reum, T., and Roots, I., A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. *Pharmacogenetics* **6**, 269-72 (1996).
183. Bachus, R., et al., Cu,Zn SOD in German families with ALS. *J Neurol Sci* **129 Suppl**, 93-5 (1995).
184. Brockmöller, J., Rost, K.L., Gross, D., Schenkel, A., and Roots, I., Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. *Pharmacogenetics* **5**, 80-8 (1995).
185. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., and Roots, I., Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. *Am J Hum Genet* **57**, 581-92 (1995).
186. Rost, K.L., Brockmöller, J., Esdorn, F., and Roots, I., Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. *J Hepatol* **23**, 268-77 (1995).
187. Brockmöller, J., Kerb, R., Drakoulis, N., Staffeldt, B., and Roots, I., Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. *Cancer Res* **54**, 4103-11 (1994).
188. Brockmöller, J. and Roots, I., Assessment of liver metabolic function. Clinical implications. *Clin Pharmacokinet* **27**, 216-48 (1994).
189. Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C.R., and Roots, I., Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. *Clin Investig* **72**, 240-8 (1994).

190. Staffeldt, B., Kerb, R., Brockmöller, J., Ploch, M., and Roots, I., Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. *J Geriatr Psychiatry Neurol* **7 Suppl 1**, S47-53 (1994).
191. Brockmöller, J., Kerb, R., Drakoulis, N., Nitz, M., and Roots, I., Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. *Cancer Res* **53**, 1004-11 (1993).
192. Bauer, S., Brockmöller, J., Kewitz, H., and Roots, I., The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. *Int J Clin Pharmacol Ther Toxicol* **30**, 540-2 (1992).
193. Brockmöller, J., Gross, D., Kerb, R., Drakoulis, N., and Roots, I., Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. *Biochem Pharmacol* **43**, 647-50 (1992).
194. Brockmöller, J., Kochling, J., Weber, W., Looby, M., Roots, I., and Neumayer, H.H., The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. *Br J Clin Pharmacol* **34**, 499-508 (1992).
195. Roots, I., Brockmöller, J., Drakoulis, N., and Loddenkemper, R., Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. *Clin Investig* **70**, 307-19 (1992).
196. Rost, K.L., Brosicke, H., Brockmöller, J., Scheffler, M., Helge, H., and Roots, I., Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. *Clin Pharmacol Ther* **52**, 170-80 (1992).
197. Weber, W., Looby, M., and Brockmöller, J., Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin. *Clin Pharmacokinet* **23**, 69-83 (1992).
198. Brockmöller, J., Staffeldt, B., and Roots, I., Evaluation of proposed sulfoxidation pathways of carbocysteine in man by HPLC quantification. *Eur J Clin Pharmacol* **40**, 387-92 (1991).
199. Kunzendorf, U., et al., Promotion of B cell stimulation in graft recipients through a mechanism distinct from interleukin-6 gene superinduction. *Transplantation* **51**, 1312-5 (1991).
200. Müller, N., Brockmöller, J., and Roots, I., Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. *Ther Drug Monit* **13**, 533-6 (1991).
201. Rost, K.L., Brockmöller, J., Weber, W., and Roots, I., Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers. *Clin Pharmacol Ther* **50**, 141-9 (1991).
202. Staffeldt, B., Brockmöller, J., and Roots, I., Determination of S-carboxymethyl-L-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent pre-column labelling. *J Chromatogr* **571**, 133-47 (1991).
203. Brockmöller, J., et al., Pharmacokinetic interaction between cyclosporin and diltiazem. *Eur J Clin Pharmacol* **38**, 237-42 (1990).
204. Kunzendorf, U., Brockmöller, J., Jochimsen, F., Roots, I., and Offermann, G., Activity of cyclosporin metabolites M17 and M1. *Transplant Proc* **22**, 1697-9 (1990).
205. Kunzendorf, U., et al., Cyclosporin drug monitoring: comparison of four immunoassays and HPLC. *Klin Wochenschr* **67**, 438-41 (1989).
206. Kunzendorf, U., Brockmöller, J., Jochimsen, F., Roots, I., and Offermann, G., Immunosuppressive properties of cyclosporin metabolites. *Lancet* **1**, 734-5 (1989).
207. Kunzendorf, U., Brockmöller, J., Jochimsen, F., Roots, I., and Offermann, G., Neurotoxicity caused by a high cyclosporine metabolite level. *Transplantation* **48**, 531-2 (1989).

208. Neumayer, H.H., Brockmöller, J., Fritschka, E., Roots, I., Scigalla, P., and Wattenberg, M., Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. *Contrib Nephrol* **76**, 131-41; discussion 141-2 (1989).
209. Offermann, G., Brockmöller, J., Kunzendorf, U., and Roots, I., Screening for abnormal cyclosporine A metabolite concentrations. *Transplant Proc* **21**, 892-4 (1989).
210. Peter, M.E., Brockmöller, J., Jonak, J., and Sprinzl, M., Identification of the N-tosyl-L-phenylalanyl chloromethylketone modification site in *Thermus thermophilus* elongation factor Tu. *FEBS Lett* **257**, 219-22 (1989).
211. Brockmöller, J. and Kamp, R.M., Cross-linked amino acids in the protein pair S13-S19 and sequence analysis of protein S13 of *Bacillus stearothermophilus* ribosomes. *Biochemistry* **27**, 3372-81 (1988).
212. Brockmöller, J., Simane, Z.J., and Roots, I., HPLC-analysis of S-carboxymethylcysteine and its sulphoxide metabolites. *Drug Metabol Drug Interact* **6**, 447-56 (1988).
213. Kunzendorf, U., Brockmöller, J., Jochimsen, F., Keller, F., Walz, G., and Offermann, G., Cyclosporin metabolites and central-nervous-system toxicity. *Lancet* **1**, 1223 (1988).
214. Brockmöller, J. and Kamp, R.M., Isolation and identification of two protein-protein crosslinks within the two subunits of *Bacillus stearothermophilus* ribosomes. *Biol Chem Hoppe Seyler* **367**, 925-35 (1986).
215. Brockmöller, J. and Kamp, R.M., Two-dimensional polyacrylamide gel electrophoresis of ribosomal proteins in the nanogram range. *Biol Chem Hoppe Seyler* **366**, 901-6 (1985).